AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.
Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide.
As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
Adam Smith shares his journey from being a HALO® customer to helping lead Indica Labs’ mission of making AI accessible to pathologists everywhere.
People of Pathology Podcast: Adam Smith – Making AI Accessible For All With Indica Labs Read More »
The Clinical Trials module in HALO AP® and HALO AP Dx provides pathologists and researchers access to comprehensive digital pathology tools for building objective, unbiased datasets that support medical research and faster drug development.
Digital Pathology in Clinical Trials: Driving Faster Drug Development Read More »
Download our brochure to learn more about how HALO AP®, the CE-IVDR-cleared image management system and HALO AP Dx, FDA 510(k)-cleared for primary diagnosis, are deployed to improve clinical workflows
HALO AP® and HALO AP Dx Brochure Read More »
26 – 28 June 2025 | Visit us at booth #19 for a live demonstration of the latest developments across our HALO clinical and life science products on June 26-28 or prebook a meeting at our booth.
As 2024 draws to a close, we at Indica Labs would like to thank the customers and collaborators who helped fill 2024 with exciting discoveries, events, and partnerships. It is a great honor to have played a part in customers’ contributions to scientific fields ranging from immuno-oncology to infectious disease, immunology, neuroscience, and metabolism.
Looking Back: Reviewing 2024 at Indica Labs Read More »
